2,281 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by First Citizens Bank & Trust Co.

Key Points

• First Citizens Bank & Trust Co. bought 2,281 Regeneron shares worth approximately $1.73 million during the third quarter, while institutional investors collectively own 83.31% of the company.
• Analysts remain broadly positive, with Regeneron carrying a “Moderate Buy” consensus rating and an average price target of $845.21. UBS upgraded the stock to “Buy” and raised its target to $978, citing the long-term opportunity for Dupixent.
• Regeneron’s latest quarterly results exceeded expectations, with EPS of $14.29 and revenue of $4.29 billion, up 16.7% year over year. Insiders have sold 8,093 shares worth about $6.5 million over the past three months, including a $3.2 million sale by director Andrew Murphy under a pre-arranged trading plan.

First Citizens Bank & Trust Co. bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,281 shares of the biopharmaceutical company's stock, valued at approximately $1,730,000.

Other hedge funds also recently bought and sold shares of the company. Signal Advisors Wealth LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $201,000. B. Riley Wealth Advisors Inc. lifted its holdings in Regeneron Pharmaceuticals by 49.8% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 620 shares of the biopharmaceutical company's stock worth $470,000 after purchasing an additional 206 shares in the last quarter. Krilogy Financial LLC lifted its holdings in Regeneron Pharmaceuticals by 31.7% in the 3rd quarter. Krilogy Financial LLC now owns 2,474 shares of the biopharmaceutical company's stock worth $1,887,000 after purchasing an additional 596 shares in the last quarter. RHS Financial LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $202,000. Finally, Forvis Mazars Wealth Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 9.2% in the 3rd quarter. Forvis Mazars Wealth Advisors LLC now owns 3,287 shares of the biopharmaceutical company's stock worth $2,493,000 after purchasing an additional 278 shares during the period. Institutional investors own 83.31% of the company's stock.

Insider Activity

In other news, insider Andrew J. Murphy sold 4,147 shares of the stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the sale, the insider directly owned 47,833 shares in the company, valued at approximately $36,960,559.10. This represents a 7.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $1,032,750.00. Following the sale, the executive vice president owned 13,134 shares of the company's stock, valued at approximately $11,163,900. This trade represents a 8.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 8,093 shares of company stock worth $6,506,845. 6.97% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Robert W. Baird increased their price objective on shares of Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the company a "neutral" rating in a report on Friday, July 31st. Royal Bank Of Canada boosted their target price on shares of Regeneron Pharmaceuticals from $737.00 to $810.00 and gave the stock a "sector perform" rating in a report on Thursday, October 8th. Zacks Research upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Monday, September 28th. JPMorgan Chase & Co. upped their target price on shares of Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the stock an "overweight" rating in a research report on Tuesday, October 6th. Finally, Sanford C. Bernstein raised their target price on shares of Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the company a "market perform" rating in a research note on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $845.21.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: UBS upgraded Regeneron to “Buy” and raised its price target to $978 from $660, arguing that the market is underestimating the long-term opportunity for Dupixent. The new target implies substantial upside and is the clearest near-term catalyst for investor optimism. Tickerreport UBS upgrade article
• Positive Sentiment: A valuation analysis says Regeneron still appears below fair value after fresh trial data and renewed attention on its immunology alliance. The report suggests the company’s earnings power may not be fully reflected in its current valuation. Regeneron stock fair value article
• Positive Sentiment: Regeneron could benefit from having paid off its balance owed to Sanofi, which had reduced the revenue reported from their partnership. The change may improve the financial contribution from the collaboration going forward. Trefis Regeneron catalysts article
• Positive Sentiment: Analysts expect double-digit bottom-line growth in the upcoming third-quarter report, keeping earnings momentum and the company’s ability to exceed estimates in focus. Barchart Regeneron earnings preview
• Neutral Sentiment: A review of biotechnology-sector results included Regeneron among the companies investors are evaluating, but provided limited new company-specific information. Yahoo Finance biotechnology earnings review
• Negative Sentiment: Director Andrew Murphy sold 4,147 shares worth approximately $3.2 million under a pre-arranged Rule 10b5-1 plan. Because the sale was scheduled in advance, it is a limited bearish signal, although it may weigh modestly on sentiment.

Regeneron Pharmaceuticals Trading Up 2.3%

REGN stock opened at $796.34 on Friday. The firm has a fifty day moving average price of $791.59 and a 200 day moving average price of $721.30. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $564.00 and a fifty-two week high of $859.34. The firm has a market cap of $81.99 billion, a PE ratio of 19.68, a price-to-earnings-growth ratio of 1.35 and a beta of 0.16. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. During the same quarter in the prior year, the firm earned $12.81 earnings per share. Regeneron Pharmaceuticals's revenue was up 16.7% on a year-over-year basis. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 47.93 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were paid a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend was Tuesday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 9.29%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron's marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.